Observational, Retrospective, Multicenter Study to Describe the Reasons for the Change of the Regimen of Antiretroviral Therapy in HIV Patients

Therapeutic Intensification Plus Immunomodulation in HIV-infected Patients

NCT01019551 ·Status: COMPLETED ·Phase: PHASE2

HIV-Infected Latin American Asylum Seekers in Europe: Insights From the EuroLatin HIV Cohort

NCT05998499 ·Status: COMPLETED

A Phase IV Study to Assess the Impact of the Change of Antiretroviral Treatment From Dual Therapy to Triple Therapy on Inflammation in Patients With HIV Infection

NCT04076423 ·Status: COMPLETED ·Phase: PHASE4

Effectiveness of Raltegravir-Based Antiretroviral Therapy in HIV-HCV Coinfected Liver Transplant Recipients

NCT02995824 ·Status: COMPLETED

Large Scale Transition to a Dolutegravir-based First-line ART in the South: Virological Response and Impact on HIV Drug Resistance in a Real Life Context (DoReaL Study)

NCT05312918 ·Status: UNKNOWN

Primary Resistance in HIV Patients in Colombia

NCT03957369 ·Status: COMPLETED

Study to Evaluate Switching From an E/C/F/TAF Fixed-Dose Combination (FDC) Regimen or a TDF Containing Regimen to B/F/TAF FDC in Human Immunodeficiency Virus-1 (HIV-1) Infected Participants Aged ≥ 65 Years

NCT03405935 ·Status: COMPLETED ·Phase: PHASE3

Immuno-Virological Efficacy of Combination With Trizivir +Tenofovir in Multiresistant HIV Patients

NCT00356616 ·Status: TERMINATED ·Phase: PHASE4

Antiretroviral Resistance Detection by Ultrasensitive Pyrosequencing of the HIV-1 Genome and Virological Response to Antiretroviral Rescue Treatment

NCT01346878 ·Status: COMPLETED

Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I

NCT02616029 ·Status: COMPLETED ·Phase: PHASE3

Dolutegravir-based Dual Therapies in HIV-infected Patients With Virological Suppression

NCT02491242 ·Status: COMPLETED

EFFICACY AND SAFETY OF A SIMPLIFICATION STRATEGY BASED ON DOLUTEGRAVIR AND DARUNAVIR / COBICISTAT VS OPTIMIZED TREATMENT IN SUPPRESSED HIV-1-INFECTED PATIENTS CARRYING ARCHIVED MULTIDRUG RESISTANCE MUTATIONS

NCT03683524 ·Status: COMPLETED ·Phase: PHASE4

Study of the Effect of Atorvastatin for Reducing Aging-related Complication in HIV-infected Patients Older Than 45 Years Receiving a Protease Inhibitor-based Regimen Versus a Raltegravir-based Regimen

NCT02577042 ·Status: COMPLETED ·Phase: PHASE4

Genotypic Tropism Testing In Proviral Dna To Guide CCR5 Antagonist Treatment In Subjects With Undetectable HIV-1 Viremia

NCT01378910 ·Status: COMPLETED ·Phase: PHASE4

Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF

NCT01252940 ·Status: COMPLETED ·Phase: PHASE3

Evaluation of the Efficacy and Safety Between Two Antiretroviral Regimens, in HIV-1-infected Treatment-naïve Subjects With Low CD4 Counts

NCT01928407 ·Status: COMPLETED ·Phase: PHASE4

CSP #512 - Options in Management With Anti-Retrovirals

NCT00050089 ·Status: COMPLETED ·Phase: NA

LoViReT (Low Viral Reservoir Treated Patients)

NCT02972931 ·Status: COMPLETED

Mathematical Modeling of the HIV Transmission Risk After Initiation of Antiretroviral Therapy in naïve HIV-infected

NCT03183154 ·Status: UNKNOWN

Duration of Dual Antiretroviral Therapy in Virologically Suppressed People Living With HIV and Factors Associated With Switching to Tritherapy : a Real-life Cohort

NCT06107140 ·Status: COMPLETED

A Study of Two Methods of Determining When to Begin or Change Anti-HIV Treatment

NCT00001069 ·Status: TERMINATED

Evaluate the Efficacy and Security of Darunavir/Ritonavir 900/100 mg Once a Day as an Antiretroviral Treatment Simplification Strategy

NCT00611039 ·Status: COMPLETED ·Phase: PHASE4

Switching From PI to RALtegravir in HIV Stable Patients

NCT00528892 ·Status: COMPLETED ·Phase: PHASE3

Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants

NCT02269917 ·Status: COMPLETED ·Phase: PHASE3

Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants

NCT03631732 ·Status: COMPLETED ·Phase: PHASE3